The global oncology clinical trials market was valued at USD 17.52 billion in 2024 and is expected to grow to USD 18.97 billion in 2025. By 2032, the market is projected to reach USD 33.98 billion, registering a compound annual growth rate (CAGR) of 8.5% during the forecast period. In 2024, North America led the oncology clinical trials market, accounting for a dominant share of 47.75%.

The oncology clinical trials market is witnessing steady growth, driven by the increasing global burden of cancer and the rising demand for innovative and targeted therapies. Clinical trials play a critical role in evaluating the safety and efficacy of new cancer treatments, including immunotherapies, targeted drugs, and combination therapies. The market is further supported by technological advancements, regulatory support, and growing investments from pharmaceutical companies and research organizations. As the need for personalized medicine and novel oncology solutions continues to rise, the oncology clinical trials market is expected to expand significantly across developed and emerging regions.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/oncology-clinical-trials-market-113466**

Market Segmentation

• By Phase: The oncology clinical trials market is segmented into Phase I, Phase II, Phase III, and Phase IV trials, with Phase III accounting for the highest share due to its complexity and large-scale patient involvement.
• By Cancer Type: Segmentation includes breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. Breast cancer trials dominate the oncology clinical trials market due to high incidence and active research pipelines.
• By Design: Segmented into interventional, observational, and expanded access trials, with interventional studies holding the largest share in the oncology clinical trials market.
• By Sponsor: Includes pharmaceutical & biopharmaceutical companies, government institutes, and academic institutions. Pharma companies are the major contributors to the oncology clinical trials market.
• By Region: Market segmentation also includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

List Of Key Oncology Clinical Trial Companies Profiled

• IQVIA Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Parexel International Corporation (U.S.)
• Medpace (U.S.)
• ICON plc (Ireland)
• Charles River Laboratories (U.S.)
• Fortrea (U.S.)
• Syneos Health (U.S.)